Literature DB >> 9376277

Modulation of c-fms proto-oncogene in an ovarian carcinoma cell line by a hammerhead ribozyme.

Y Yokoyama1, S Morishita, Y Takahashi, M Hashimoto, T Tamaya.   

Abstract

Co-expression of macrophage colony-stimulating factor (M-CSF) and its receptor (c-fms) is often found in ovarian epithelial carcinoma, suggesting the existence of autocrine regulation of cell growth by M-CSF. To block this autocrine loop, we have developed hammerhead ribozymes against c-fms mRNA. As target sites of the ribozyme, we chose the GUC sequence in codon 18 and codon 27 of c-fms mRNA. Two kinds of ribozymes were able to cleave an artificial c-fms RNA substrate in a cell-free system, although the ribozyme against codon 18 was much more efficient than that against codon 27. We next constructed an expression vector carrying a ribozyme sequence that targeted the GUC sequence in codon 18 of c-fms mRNA. It was introduced into TYK-nu cells that expressed M-CSF and its receptor. Its transfectant showed a reduced growth potential. The expression levels of c-fms protein and mRNA in the transfectant were clearly decreased with the expression of ribozyme RNA compared with that of an untransfected control or a transfectant with the vector without the ribozyme sequence. These results suggest that the ribozyme against GUC in codon 18 of c-fms mRNA is a promising tool for blocking the autocrine loop of M-CSF in ovarian epithelial carcinoma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9376277      PMCID: PMC2228084          DOI: 10.1038/bjc.1997.496

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  25 in total

1.  Expression and amplification of the HER-2/neu (c-erbB-2) protooncogene in epithelial ovarian tumors and cell lines.

Authors:  F L Tyson; C M Boyer; R Kaufman; K O'Briant; G Cram; J R Crews; J T Soper; L Daly; W C Fowler; J S Haskill
Journal:  Am J Obstet Gynecol       Date:  1991-09       Impact factor: 8.661

2.  Co-expression of M-CSF transcripts and protein, FMS (M-CSF receptor) transcripts and protein, and steroid receptor content in adenocarcinomas of the ovary.

Authors:  F Kommoss; J Wölfle; T Bauknecht; J Pfisterer; M Kiechle-Schwarz; A Pfleiderer; W Sauerbrei; R Kiehl; B M Kacinski
Journal:  J Pathol       Date:  1994-10       Impact factor: 7.996

3.  Macrophage colony-stimulating factor (CSF-1) enhances invasiveness in CSF-1 receptor-positive carcinoma cell lines.

Authors:  A E Filderman; A Bruckner; B M Kacinski; N Deng; H G Remold
Journal:  Cancer Res       Date:  1992-07-01       Impact factor: 12.701

Review 4.  Cell growth regulation in epithelial ovarian cancer.

Authors:  R C Bast; C M Boyer; I Jacobs; F J Xu; S Wu; J Wiener; M Kohler; A Berchuck
Journal:  Cancer       Date:  1993-02-15       Impact factor: 6.860

5.  Colony stimulating factor-1 stimulates Ishikawa cell proliferation and lipocortin II synthesis.

Authors:  J D Croxtall; J W Pollard; F Carey; R A Forder; J O White
Journal:  J Steroid Biochem Mol Biol       Date:  1992-04       Impact factor: 4.292

6.  Modulation of platelet-derived growth factor-beta mRNA expression and cell growth in a human mesothelioma cell line by a hammerhead ribozyme.

Authors:  T Dorai; H Kobayashi; J F Holland; T Ohnuma
Journal:  Mol Pharmacol       Date:  1994-09       Impact factor: 4.436

7.  Oxidative stress induces NF kappa B DNA binding and inducible NOS mRNA in human epithelial cells.

Authors:  I M Adcock; C R Brown; O Kwon; P J Barnes
Journal:  Biochem Biophys Res Commun       Date:  1994-03-30       Impact factor: 3.575

Review 8.  Signal transduction by the macrophage-colony-stimulating factor receptor (CSF-1R).

Authors:  M F Roussel
Journal:  J Cell Sci Suppl       Date:  1994

Review 9.  CSF-1 and its receptor in ovarian, endometrial and breast cancer.

Authors:  B M Kacinski
Journal:  Ann Med       Date:  1995-02       Impact factor: 4.709

10.  A pregnancy defect in the osteopetrotic (op/op) mouse demonstrates the requirement for CSF-1 in female fertility.

Authors:  J W Pollard; J S Hunt; W Wiktor-Jedrzejczak; E R Stanley
Journal:  Dev Biol       Date:  1991-11       Impact factor: 3.582

View more
  3 in total

Review 1.  Kinase inhibitors in cancer therapy: a look ahead.

Authors:  H H Sedlacek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

2.  Development of antithrombotic miniribozymes that target peripheral tryptophan hydroxylase.

Authors:  Jens-Uwe Peter; Natalia Alenina; Michael Bader; Diego J Walther
Journal:  Mol Cell Biochem       Date:  2006-08-22       Impact factor: 3.396

Review 3.  Genetic factors in ovarian carcinoma.

Authors:  A J Li; B Y Karlan
Journal:  Curr Oncol Rep       Date:  2001-01       Impact factor: 5.075

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.